Over 90 Total Lots Up For Auction at One Location - WA 04/08

AngioDynamics provides updates on oncology and vascular access businesses

Press releases may be edited for formatting or style | August 16, 2018 Business Affairs Cardiology Operating Room
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today provided a corporate update on enhancements made to its Oncology business and acknowledged a recent, favorable U.S. District Court ruling that impacts its Vascular Access business.

Oncology Business

As part of its strategic focus on building a continuum of care within the oncology space, AngioDynamics has announced the acquisition of the BioSentry Tract Sealant System (BioSentry) technology from Surgical Specialties, LLC, a medical device company headquartered in Westwood, Massachusetts.

The acquisition immediately enhances AngioDynamics’ Oncology business, adding a commercialized, clinically proven product that minimizes the occurrence of pneumothorax, or PTX, the most common complication of CT-guided percutaneous lung biopsy1. The technology delivers a proprietary hydrogel plug, which prevents air leakage during a CT-guided percutaneous lung biopsy and helps mitigate the risk of PTX. In 2010, a published clinical trial involving 339 patients at 15 different sites showed BioSentry technology with an 85% clinical success rate, compared to 69% in the control group1.

“The addition of the BioSentry technology to our oncology portfolio is the type of strategic and thoughtful acquisition that aligns with our plans to deliver safer, clinically relevant, and economically favorable solutions that improve patient outcomes,” said Jim Clemmer, President and CEO of AngioDynamics. “By expanding our offerings in the oncology discipline, we are creating an opportunity to serve patients who may also benefit from our core products earlier in their disease state.”

Approved by the Food and Drug Administration (FDA) in December 2012, the BioSentry System became commercially available in 2013 and is also CE Mark approved in Europe. In addition to acquiring the BioSentry System, Surgical Specialties’ 12-person commercial organization will join AngioDynamics and expand the reach of its Oncology business.

BioSentry’s trailing 12-months revenues exceeded $5 million, and the acquisition is expected to be neutral to earnings on an adjusted basis.

SunTrust Robinson Humphrey served as the exclusive financial advisor to AngioDynamics.

Vascular Access Business

In May of 2017, AngioDynamics filed a lawsuit against C.R. Bard (Bard) for violating United States antitrust laws with its practice of illegally tying tip location system sales to its line of peripherally inserted central catheters (PICCs). On Monday, August 6, the U.S. District Court for the Northern District of New York rejected – in its entirety – C.R. Bard’s motion to dismiss AngioDynamics’ lawsuit against it.

You Must Be Logged In To Post A Comment